Document is current
Any future updates will be listed below
-
Authors
Elangovan, H.
Akbary, K.
Rastogi, A.
Wee, A.
Soon, G.
Adams, L.
Carr-Boyd, E.
Clouston, A.
Cooper, C. L.
Chan, W. K.
Dan, Y. Y.
Dela-Cruz, R.
Goh, G.
Hamid, S. S.
Huang, D. Q.
Kawaguchi, T.
Kim, W.
Kim, S. U.
Jia, J. D.
Liu, C. J.
Liu, F.
Leow, W. Q.
Muthiah, M. D.
Ng, I.
Payawal, D.
Pan, A. F.
Pervez, S.
Shiha, G.
Tanwandee, T.
Tanaka, Y.
Thiyaphat, L.
Vij, M.
Yilmaz, Y.
Yilmaz, F.
Yu, M. L.
Zalata, K.
Zheng, M. H.
Fan, J. G.
Sarin, S. K.
Wong, V.
George, J. https://orcid.org/0000-0002-8421-5476
-
Funding
Funding for this research was provided by:
The University of Sydney
- License Information
-
More Information
Article History
Received: 18 November 2025
Accepted: 10 April 2026
First Online: 13 May 2026
Declarations
:
: JG has served on advisory boards and/or has received honoraria for talks from Novo Nordisk, Astra Zeneca, Roche, BMS, Pfizer, Cincera, Histoindex, Pharmaxis, Boehringer Mannheim, CSL, Norgine, Gilead, and Eisai. KA is an employee of Histoindex. YYD has research collaborations with funding from Histoindex. WKC has served as a consultant or advisory board member for Abbott, Abbvie, Boehringer Ingelheim, IPSEN, Kowa, Novo Nordisk, Roche, and Zuellig Pharma; as a speaker for Abbott, Echosens, Hisky Medical, Novo Nordisk, Roche and Viatris; and has received research grants from Abbott and Roche. YY has served as a consultant for Zydus and an adviser for Novo Nordisk. GS received a fee-for-service from Clinnovate Health. MLY receives research support from Abbvie, Abbott Diagnostic, BMS, Gilead, Merck, Novo Nordisc and Roche diagnostics, serves as a consultant of Abbvie, Abbott Diagnostic, BMS, Gilead, Novo Nordisc, Roche and Roche diagnostics, and serves as a speaker of Abbvie, BMS, Eisai, Gilead, Roche and Roche diagnostics. TK received lecture fees from ASKA Pharmaceutical Co., Ltd., Taisho Pharmaceutical Co., Ltd., Kowa Company, Ltd., AbbVie GK., Eisai Co., Ltd., EA Pharma Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., Sumitomo Pharma Co., Ltd., Novo Nordisk Pharma Ltd., Otsuka Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K. AW has received a fee-for-service from Histoindex. SUK has served as an advisory committee member of Gilead Sciences, Bayer, Eisai and Novo Nordisk. He is a speaker for Gilead Sciences, GSK, Bayer, Eisai, Abbive, EchoSens, MSD, Eisai, Otsuka and Bristol-Myers Squibb. He has also received a research grant from Abbive and Bristol-Myers Squibb. SUK is an Editorial Board member of Clinical and Molecular Hepatology, Gut and Liver, Journal of Gastroenterology and Hepatology, and Clinical Gastroenterology and Hepatology. YT has received research funding and honoraria from AbbVie GK, Otsuka Pharmaceutical Co., Ltd., Gilead, G AstraZeneca, ASKA Pharmaceutical Co., Ltd, GSK, Eisai and Chugai Pharmaceutical Co., Ltd. MHZ serves as a speaker for AstraZeneca, Hisky Medical Technologies, and Novo Nordisk; as a consultant for Boehringer Ingelheim and Eieling Technology; and has received consulting fees from Boehringer Ingelheim.
: This survey was conducted in accordance with the European Pharmaceutical Market Research Association (EphMRA) code of ethics.
